As the COVID-19 epidemic continues to impact markets, it has also created new opportunities and challenges for M&A transactions in the life sciences industry. Join us as our panel of seasoned life sciences executives, financial and legal advisors share their views on the current environment, trends and strategies, and suggestions for companies to set themselves up for success. Our discussion will be moderated by Effie Toshav, Doug Cogen and Marshall Smith.

Speakers:

Josh Bilenker
, Chief Executive Officer, Loxo Oncology at Lilly and Operating Partner, Aisling Capital
Jacob Van Naarden
, Chief Operating Officer, Loxo Oncology at Lilly
Marshall Smith
, Global Head of the Healthcare Investment Banking, Goldman Sachs
Effie Toshav
, Partner, Corporate, Fenwick
Doug Cogen
, Co-Chair, Mergers & Acquisitions, Fenwick

    Login

    Don’t have an account yet?

    Register